Coherus Oncology (CHRS) Receivables (2013 - 2026)

Coherus Oncology (CHRS) has 13 years of Receivables data on file, last reported at $22.5 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 63.95% year-over-year to $22.5 million; the trailing twelve-month figure through Mar 2026 stood at $22.5 million (down 63.95% YoY), and the FY2025 full-year result was $18.4 million, down 84.94% from the prior year.
• Receivables climbed to $22.5 million in Q1 2026, from $18.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $313.6 million in Q2 2024 to a low of $18.4 million in Q4 2025.
• A 5-year average of $149.8 million and a median of $119.6 million in 2025 frame the typical range for Receivables.
• Across the five-year window, Receivables jumped 180.06% in 2024 and tumbled 84.94% in 2025, its largest moves.
• Tracing CHRS's Receivables over 5 years: stood at $110.0 million in 2022, then surged by 136.92% to $260.5 million in 2023, then plunged by 53.04% to $122.3 million in 2024, then plunged by 84.94% to $18.4 million in 2025, then rose by 22.22% to $22.5 million in 2026.
• Business Quant data shows CHRS's Receivables at $22.5 million in Q1 2026, $18.4 million in Q4 2025, and $250.5 million in Q3 2025.